# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-006722
Filing Date
2022-04-29
Accepted
2022-04-29 16:22:54
Documents
6
Period of Report
2022-06-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tern-def14a-2022.htm | DEF 14A | 837599
2 | GRAPHIC | img192746610_0.jpg | GRAPHIC | 659680
3 | GRAPHIC | img192746610_1.jpg | GRAPHIC | 659680
4 | GRAPHIC | img192746610_2.jpg | GRAPHIC | 659680
5 | GRAPHIC | img192746610_3.jpg | GRAPHIC | 1099019
6 | GRAPHIC | img192746610_4.jpg | GRAPHIC | 336939
| Complete submission text file | 0000950170-22-006722.txt |  | 5536640

Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39926 | Film No.: 22875927
SIC: 2834 Pharmaceutical Preparations